- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
- Book
- March 2019
- 282 Pages
- Report
- January 2025
- 132 Pages
Global
From €897EUR$950USD£763GBP
- Report
- March 2025
- 239 Pages
China
From €3778EUR$4,000USD£3,213GBP
- SWOT Analysis
- October 2024
Global
From €708EUR$750USD£602GBP
- Report
- March 2024
- 132 Pages
Global
From €897EUR$950USD£763GBP
- Report
- November 2021
- 575 Pages
Global
From €3778EUR$4,000USD£3,213GBP
- Report
- September 2024
- 230 Pages
Global
From €2507EUR$2,655USD£2,133GBP
- Report
- September 2022
- 172 Pages
Global
From €3371EUR$3,570USD£2,868GBP
- Book
- November 2013
Global

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more